Early-stage clinical trials
Automated articles on Early-stage clinical trials, built every day from SEC filings, prices and our own datasets.
All topics · Dilution · Offerings · Convertible notes · FDA approval · Licensing and milestone payments · At-the-market offering · Delistings · Mergers and acquisitions · Restaurants · Casinos · Foreign private issuer · Material weakness · Early-stage clinical trials · Oncology · FDA setbacks · Reverse split · Private placement (PIPE) · Warrants and inducements · Biofuels and renewable natural gas · Insider buying · Debt financing · Divestitures · Solar · Artificial intelligence · Equity line of credit · Late-stage clinical trials · Daily feature · Going-concern doubt · Week ahead · Customer concentration · Late filings · Weekly roundups · Rates and the dollar · Banking · Quarterly results · Dual-class shares · Inflation and interest rates · Share buybacks · AI data centers · Executive turnover · GPUs and accelerators · Big movers · IPO · Public offerings · SPAC · China exposure · Convertible preferred stock · Natural gas and LNG · Cryptocurrency · Bankruptcy · Tobacco and vaping · Related-party loans · Nasdaq deficiency notice · Payments and fintech · Alcoholic beverages · Oil and gas production · Delisting · Aerospace and aviation · Tariffs · Medical devices · 13G holders · Carbon and clean energy credits · Semiconductors · Cannabis · Electric vehicles · Name or ticker change · Aesthetics and dermatology · Pet products · Stablecoins · Critical minerals · Gold mining · Mineral exploration · Auditor changes · Drones · Cell and gene therapy · Defense and military · Exchange listing notices · OTC quotation · Battery energy storage · Authorized share increase · 13D stakes · Robotics · Market wrap · Dividend payments · Spin-offs · Carbon capture · Impairment charges · Firearms and ammunition · Reverse merger · Securities class actions · Generative AI · Layoffs and restructuring · Asset management and BDCs · Hydrogen and fuel cells · Joint ventures · REITs and real estate · Reverse splits · Data centers · Backlog and contracted revenue · Trucking and logistics · Agriculture · Wind power · Video games and esports · War and geopolitical risk · Insurance carriers · Medicare and Medicaid reimbursement
On Nov 16, 2026, Vir Biotechnology Inc. (VIR) filed a 424B5: a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)
November 16, 2026 · data as of 2026-11-16
On Nov 16, 2026, MapLight Therapeutics Inc. (MPLT) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 16, 2026)
November 16, 2026 · data as of 2026-11-16
Surrozen Inc. (SRZN) filed a 424B5 on Nov 16, 2026, a prospectus supplement for a sale from its shelf. (SEC EDGAR, 424B5, Nov 16, 2026)
November 16, 2026 · data as of 2026-11-16
Alumis Inc. (ALMS) reported substantial doubt, in its 10-Q filed Nov 12, 2026, about whether it can keep operating as a going concern. (SEC EDGAR, 10-Q, 2026-11-12)
November 15, 2026 · data as of 2026-11-12
In its 10-Q, filed Nov 10, 2026, Context Therapeutics Inc. (CNTX) disclosed substantial doubt that it can carry on as a going concern. (SEC EDGAR, 10-Q, Nov 10, 2026)
November 14, 2026 · data as of 2026-11-10
Alumis Inc. (ALMS) reported substantial doubt, in its 10-Q filed Nov 12, 2026, about whether it can keep operating as a going concern. (SEC EDGAR, 10-Q, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
In a Schedule 13G filed Nov 12, 2026, Adage Capital Management, L.P. reported 2.1 million shares of First Tracks Biotherapeutics Inc. (TRAX) as of Sep 30, 2026, 5.8% of the class. (SEC EDGAR, SCHEDULE 13G, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
Vir Biotechnology Inc. (VIR) filed a 424B5 on Nov 12, 2026 whose text describes an at-the-market offering, shares sold into the market over time through a sales agent. (SEC EDGAR, 424B5, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
The 10-Q that Eikon Therapeutics Inc. (EIKN) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
The 10-Q that Evommune Inc. (EVMN) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
The 10-Q that Alumis Inc. (ALMS) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
Foghorn Therapeutics Inc. (FHTX) filed its 10-Q on Nov 9, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)
November 14, 2026 · data as of 2026-11-09
The 10-Q that Ovid Therapeutics Inc. (OVID) filed on Nov 10, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)
November 14, 2026 · data as of 2026-11-10
Relmada Therapeutics Inc. (RLMD) filed its 10-Q on Nov 12, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
Aura Biosciences Inc. (AURA) filed its 10-Q on Nov 9, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)
November 14, 2026 · data as of 2026-11-09
Tonix Pharmaceuticals Holding Corp. (TNXP) filed its 10-Q on Nov 9, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)
November 14, 2026 · data as of 2026-11-09
The 10-Q that Altimmune Inc. (ALT) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
The 10-Q that Zymeworks Inc. (ZYME) filed on Nov 9, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 9, 2026)
November 14, 2026 · data as of 2026-11-09
Prime Medicine Inc. (PRME) filed its 10-Q on Nov 12, 2026, covering the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
Addex Therapeutics Ltd (ADXN) closed at $5.29 on Nov 12, 2026, up 83.0% from $2.89. (Daily closes (Yahoo Finance chart endpoint), Nov 12, 2026)
November 14, 2026 · data as of 2026-11-12
Automated from SEC filings and market data. No AI. For information only. Not investment advice.